Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges

References

• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Chohan K, Ansell SM. Current salvage therapies in Hodgkin lymphoma. Leuk Lymphoma. 2022 Jun;63(6):1267–1280. doi: 10.1080/10428194.2021.2024819
   PubMed Web of Science ®Google Scholar
• Voorhees TJ, Beaven AW. Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma. Cancers (Basel). 2020 Oct 8;12(10):2887. doi: 10.3390/cancers12102887
   PubMed Web of Science ®Google Scholar
• Driessen J, Tonino SH, Moskowitz AJ, et al. How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):240–246. doi: 10.1182/hematology.2021000311
   PubMedGoogle Scholar
• Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011 Apr 21;117(16):4208–4217. doi: 10.1182/blood-2010-09-288373
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993 Apr 24;341(8852):1051–1054. doi: 10.1016/0140-6736(93)92411-L
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002 Jun 15;359(9323):2065–2071. doi: 10.1016/S0140-6736(02)08938-9
   PubMed Web of Science ®Google Scholar
• Brockelmann PJ, Muller H, Gillessen S, et al. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia. 2022 Mar;36(3):772–780. doi: 10.1038/s41375-021-01442-8
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 Dec 20;132(25):2639–2642. doi: 10.1182/blood-2018-07-861641
   PubMed Web of Science ®Google Scholar
• Sureda A, Andre M, Borchmann P, et al. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. BMC Cancer. 2020 Nov 10;20(1):1088. doi: 10.1186/s12885-020-07561-2
   PubMed Web of Science ®Google Scholar
• Wilke C, Cao Q, Dusenbery KE, et al. Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):94–102. doi: 10.1016/j.ijrobp.2017.05.007
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012 Feb 16;119(7):1665–1670. doi: 10.1182/blood-2011-10-388058
   PubMed Web of Science ®Google Scholar
• Sucak GT, Ozkurt ZN, Suyani E, et al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329–1336. doi: 10.1007/s00277-011-1209-0
   PubMed Web of Science ®Google Scholar
• Yhim HY, Eshet Y, Metser U, et al. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. Am J Hematol. 2022 May;97(5):583–591. doi: 10.1002/ajh.26500
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183–2189. doi: 10.1200/JCO.2011.38.0410
   PubMed Web of Science ®Google Scholar
• Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013 Nov;54(11):2531–2533. doi: 10.3109/10428194.2013.798868
   PubMed Web of Science ®Google Scholar
• Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2022 Jul 28;387(4):310–320. doi: 10.1056/NEJMoa2206125
   PubMed Web of Science ®Google Scholar
• Ansell SM, Brockelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023 Oct 24;7(20):6266–6274. doi: 10.1182/bloodadvances.2023010334
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019 Oct 3;134(14):1144–1153. doi: 10.1182/blood.2019000324
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021 Apr;22(4):512–524. doi: 10.1016/S1470-2045(21)00005-X
   PubMedGoogle Scholar
• Herrera AF, LeBlanc ML, Castellino SM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol. 2023;41(17_suppl):LBA4–LBA4. doi: 10.1200/JCO.2023.41.17_suppl.LBA4
   Web of Science ®Google Scholar
• Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023 Sep 7;142(10):878–886. doi: 10.1182/blood.2022019386
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007 Jun;18(6):1071–1079. doi: 10.1093/annonc/mdm090
   PubMed Web of Science ®Google Scholar
• Moccia AA, Hitz F, Hoskins P, et al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leuk Lymphoma. 2017 Feb;58(2):324–332. doi: 10.1080/10428194.2016.1193852
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002 Oct;13(10):1628–1635. doi: 10.1093/annonc/mdf221
   PubMed Web of Science ®Google Scholar
• Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999 May;10(5):593–595. doi: 10.1023/A:1026454831340
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Onco Targets Ther. 2014;7:2093–2100. doi: 10.2147/OTT.S70264
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001 Feb 1;97(3):616–623. doi: 10.1182/blood.V97.3.616
   PubMed Web of Science ®Google Scholar
• Proctor SJ, Jackson GH, Lennard A, et al. Strategic approach to the management of Hodgkin’s disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a northern region lymphoma group study (UK). Ann Oncol. 2003;14 Suppl 1:i47–50. doi: 10.1093/annonc/mdg710
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des lymphomes de l’Adulte H89 trial. J Clin Oncol. 2002 Jan 15;20(2):467–475. doi: 10.1200/JCO.20.2.467
   PubMed Web of Science ®Google Scholar
• Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin’s disease. Br J Haematol. 1998 Nov;103(2):533–535. doi: 10.1046/j.1365-2141.1998.00989.x
   PubMed Web of Science ®Google Scholar
• Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007 Jan;92(1):35–41. doi: 10.3324/haematol.10661
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010 Mar;148(6):890–897. doi: 10.1111/j.1365-2141.2009.08037.x
   PubMed Web of Science ®Google Scholar
• Labrador J, Cabrero-Calvo M, Perez-Lopez E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. Ann Hematol. 2014 Oct;93(10):1745–1753. doi: 10.1007/s00277-014-2114-0
   PubMed Web of Science ®Google Scholar
• Santoro A, Mazza R, Pulsoni A, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020 Jan 14;4(1):136–140. doi: 10.1182/bloodadvances.2019000984
   PubMed Web of Science ®Google Scholar
• Eyre TA, Phillips EH, Linton KM, et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. Br J Haematol. 2017 Nov;179(3):471–479. doi: 10.1111/bjh.14898
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015 Dec;21(12):2136–2140. doi: 10.1016/j.bbmt.2015.07.018
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Cantonetti M, et al. Brentuximab vedotin in transplant-naive relapsed/refractory Hodgkin lymphoma: experience in 30 patients. Oncology. 2015 Dec;20(12):1413–1416. doi: 10.1634/theoncologist.2015-0227
   Google Scholar
• Merryman RW, Redd RA, Nishihori T, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 Mar 23;5(6):1648–1659. doi: 10.1182/bloodadvances.2020003556
   PubMed Web of Science ®Google Scholar
• Halahleh K, Al Sawajneh S, Saleh Y, et al. Pembrolizumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after autologous transplant and in transplant-naive patients. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):589–595. doi: 10.1016/j.clml.2022.02.009
   PubMed Web of Science ®Google Scholar
• Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s oncology group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 Sep;19(9):1229–1238. doi: 10.1016/S1470-2045(18)30426-1
   PubMed Web of Science ®Google Scholar
• Broccoli A, Argnani L, Botto B, et al. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J. 2019 Dec 11;9(12):100. doi: 10.1038/s41408-019-0265-x
   PubMedGoogle Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018 Jul 5;132(1):40–48. doi: 10.1182/blood-2017-11-815183
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group). Ann Oncol. 2019 Apr 1;30(4):612–620. doi: 10.1093/annonc/mdz009
   PubMed Web of Science ®Google Scholar
• Abuelgasim KA, Alzahrani M, Alsharhan Y, et al. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2019 Jul;54(7):1168–1172. doi: 10.1038/s41409-019-0454-z
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica. 2021 Apr 1;106(4):1129–1137. doi: 10.3324/haematol.2019.243238
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schoder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017 Nov 16;130(20):2196–2203. doi: 10.1182/blood-2017-06-788877
   PubMed Web of Science ®Google Scholar
• Herrera AF, Palmer J, Martin P, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018 Mar 1;29(3):724–730. doi: 10.1093/annonc/mdx791
   PubMed Web of Science ®Google Scholar
• Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021 Aug 12;138(6):427–438. doi: 10.1182/blood.2020009178
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Hong F, Ambinder RF, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep;7(9):e660–e670. doi: 10.1016/S2352-3026(20)30221-0
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Jegede O, Ansell SM, et al. Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412). Blood. 2023;142(Supplement 1):607–607. doi: 10.1182/blood-2023-184531
   PubMedGoogle Scholar
• O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018 Feb;19(2):257–266. doi: 10.1016/S1470-2045(17)30912-9
   PubMed Web of Science ®Google Scholar
• Bryan LJ, Casulo C, Allen PB, et al. Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial. JAMA Oncol. 2023 May 1;9(5):683–691. doi: 10.1001/jamaoncol.2022.7975
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Shah G, Schoder H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 2021 Oct 1;39(28):3109–3117. doi: 10.1200/JCO.21.01056
   PubMed Web of Science ®Google Scholar
• Mei MG, Lee HJ, Palmer JM, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022 Jun 23;139(25):3605–3616. doi: 10.1182/blood.2022015423
   PubMed Web of Science ®Google Scholar
• Harker-Murray P, Mauz-Körholz C, Leblanc T, et al. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023 Apr 27;141(17):2075–2084. doi: 10.1182/blood.2022017118
   PubMed Web of Science ®Google Scholar
• Sureda-Balari A, Terol MJ, Domingo-Domènech E, et al. T098: brentuximab vedotin plus ESHAP (BRESHAP) versus ESHAP in patients with relapsed or refractory classical Hodgkin’s lymphoma. interim results of the BRESELIBET prospective clinical trial. Hemasphere. 2022;6:45. doi: 10.1097/01.HS9.0000890960.29449.17
   Google Scholar
• Desai SH, Spinner MA, David K, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023 Mar;98(3):464–471. doi: 10.1002/ajh.26827
   PubMed Web of Science ®Google Scholar
• Shotton R, Kirkwood AA, Northend M, et al. Real world outcomes and responses to second-line therapy in relapsed/refractory Hodgkin lymphoma: a multicentre UK study. Hematol Oncol. 2021;39(S2). doi: 10.1002/hon.106_2880
   Google Scholar
• Driessen J, de Wit F, Herrera AF, et al. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis. Blood Adv. 2024;8(11):2740–2752. doi: 10.1182/bloodadvances.2023012145
   PubMed Web of Science ®Google Scholar
• Svoboda J, Ballard HJ, Bair SM, et al. Current selection patterns, toxicities and outcomes of pre-transplant salvage treatment regimens in patients with relapsed/refractory Hodgkin lymphoma: results of a multicenter retrospective analysis. Blood. 2019;134(Supplement_1):2855–2855. doi: 10.1182/blood-2019-123741
   Google Scholar
• Borchmann P, Moccia AA, Greil R, et al. BRECADD is non-inferior to EBEACOPP in patients with advanced stage classical Hodgkin lymphoma: efficacy results of the GHSG phase III HD21 trial. Hematol Oncol. 2023;41(S2):881–882. doi: 10.1002/hon.3196_LBA5
   Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet. 2017 Dec 23;390(10114):2790–2802. doi: 10.1016/S0140-6736(17)32134-7
   PubMed Web of Science ®Google Scholar
• Federico M, Fortpied C, Stepanishyna Y, et al. Long-term follow-up of the response-adapted intergroup EORTC/LYSA/FIL H10 trial for localized Hodgkin lymphoma. J Clin Oncol. 2024 Jan 1;42(1):19–25. doi: 10.1200/JCO.23.01745
   PubMed Web of Science ®Google Scholar
• Luminari S, Fossa A, Trotman J, et al. Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial. J Clin Oncol. 2024 Jan 1;42(1):13–18. doi: 10.1200/JCO.23.01177
   PubMed Web of Science ®Google Scholar
• Daw S, Hasenclever D, Mascarin M, et al. Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet pediatric Hodgkin lymphoma group. Hemasphere. 2020 Feb;4(1):e329. doi: 10.1097/HS9.0000000000000329
   PubMed Web of Science ®Google Scholar
• Alig SK, Shahrokh Esfahani M, Garofalo A, et al. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature. 2024 Jan;625(7996):778–787. doi: 10.1038/s41586-023-06903-x
   PubMed Web of Science ®Google Scholar
• Maco M, Kupcova K, Herman V, et al. Circulating tumor DNA in Hodgkin lymphoma. Ann Hematol. 2022 Nov;101(11):2393–2403. doi: 10.1007/s00277-022-04949-x
   PubMed Web of Science ®Google Scholar